Abstract: Objective The aim of this study was to re-observe the clinical efficacy of splenectomy (SPL) and portal-azygous disconnection (PAD) in treating patients with hepatitis B cirrhosis and portal hypertension. Methods A total of 87 patients with hepatitis B cirrhosis and portal hypertension were enrolled in our hospital between Februar y 2017 and November 2019, and 45 patients out of them received SPL and esophagogastric devascularization (observation group) and 42 patients underwent percutaneous transhepatic variceal embolization ( PTVE) and partial splenic embolization. The body mass index (BMI), mid-upper arm circumference (MUAC) and riceps skinfold thickness (RST) were measured. The portal venous flow (PVF), superior mesenteric venous flow (SMVF) and splenic venous flow ( SVF) were measured by sonography. Results One month after operation, the BMI, MUAC and RST in the observation were (21.5±1.3)kg/m², (22.1±1.0)cm and (10.3±1.0)mm, not significantly different as compared to in the control; the PVF and SMVF were (670.9±46.2)ml/min and (583.5±69.0)ml/min, significantly different compared to in the control; serum albumin levels was (34.0±1.4)g/L, significantly higher than in the control; the incidence of post-operational complications was 8.9%, much lower than 38.1%(P<0.05) in the control. Conclusion The classic splenectomy and esophagogastric devascularization combination is still an important choice of treatment for patients with hepatitis B cirrhosis and portal hypertension, which might reduce the portal pressure, improve liver function and liver blood perfusion with fewer complications.

Key words: Liver cirrhosis, Portal hypertension, Splenectomy, Esophagogastric devascularization, Therapy